Jared Gollob, Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR), sold 119,152 shares at $60.37 ($7.3M) on 2025-10-15, disclosed to the SEC on 2025-10-15.
Scheduled sale ($7.3M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.37 | 29,264 | $1.8M | 24.1% |
| 2 | $60.37 | 29,264 | $1.8M | 24.1% |
| 3 | $61.49 | 8,963 | $551K | 7.5% |
| 4 | $61.49 | 8,963 | $551K | 7.5% |
| 5 | $62.72 | 14,896 | $934K | 12.8% |
| 6 | $62.72 | 14,896 |
| $934K |
| 12.8% |
| 7 | $63.09 | 6,453 | $407K | 5.6% |
| 8 | $63.09 | 6,453 | $407K | 5.6% |
| Total | $61.42 avg | 119,152 | $7.3M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $187K | — | Filing → |
| KYMR | SELL | 2025-03-03 | $317K | — | Filing → |
| KYMR | SELL | 2024-07-16 | $3.6M | — | Filing → |